Visible boosts sales force as figures decline:
This article was originally published in Clinica
Executive Summary
Canadian company Visible Genetics, which develops and markets DNA sequencing hardware and tests for breast cancer and HIV, made sales of $313,000 for the first quarter of 1997, down from its $824,000 in the fourth quarter of 1996 - its first commercial trading period. Losses increased to $1.9 million from $1.0 million in the previous period. Visible has also increased its North American sales force to five, including west coast sales manager Andrew Loehr from Boehringer Mannheim Biochemicals